Diagnostic benefits of mindin as a prostate cancer biomarker

Abstract

Summary Background It has been shown that decreased expression and activity of extracellular matrix protein mindin correlate with various types of cancers including breast, colon and lung cancers. The aim of the presented study was to investigate the serum mindin levels in prostate cancer. Methods Mindin concentrations in serum were measured in 56 patients with prostate cancer (mean age 68 years) and in control group of 29 healthy men (mean age 64 years) using commercially available enzymatic immunoassay (Cusabio, WuHan, China). The patients were divided with respect to the severity of the disease into two groups according to the EAU guidelines (stage 1, 2 – less severe tumours, stage 3, 4 – severe tumours). Results Serum mindin concentrations were significantly elevated in the group of healthy individuals unlike in the patients with prostate cancer (2.12 ng/mL vs 0.78 ng/mL, with P=0.0007, AUC=0.705). Patients with less severe tumours (stage 1, 2) and severe tumours (stage 3, 4) had significantly decreased levels of S-mindin as well (P=0.0037), although the difference in serum mindin concentrations between the patients with less severe and severe tumours was not significant. Conclusions Concentrations of mindin were decreased in patients with prostate cancer and reduced in patients with less severe prostate cancer as well. Mindin appears to be a promising diagnostic marker useful in the diagnosis of prostate cancer.

MINDIN Exerts Protumorigenic Actions on Primary Prostate Tumors via Downregulation of the Scaffold Protein NHERF-1

“…Altogether, these observations might suggest that MINDIN increases in the serum of patients with certain types of cancers such as prostate or ovarian cancer [51], while decreasing in other types. However, a decrease in serum levels of MINDIN in prostate cancer patients compared to control subjects has also been reported in two independent studies [52,53]. These discrepancies could be attributable to different assay methodologies but are more likely caused by differences in the selection of control subjects.…”

The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology

“…The molecular findings at the genomic and transcriptomic levels were interrogated specifically with respect to the treatment options. Some novel biomarkers for prognosis and diagnosis, beyond the Gleason score and PSA level, have been proposed for prostate cancer management, but these were not investigated in detail for our case [ 48 , 49 ].…”